Evidence map›Paper›PMID 38487540›Full record

ArticleFrontiers in immunology2024

The IFIH1-A946T risk variant promotes diabetes in a sex-dependent manner.

Amanda J Stock, Pierina Gonzalez Paredes, Luciana Previato de Almeida, Stanley D Kosanke, Srinivaas Chetlur, Hannah Budde, Paul Wakenight, Theresa A Zwingman, Aaron B I Rosen, Eric J Allenspach and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. ProtectiveiScience · 2026
    Article
  2. Article
  3. Review
  4. Pathogenesis and advances in immunotherapy for type 1 diabetes treatment.Biotechnology reports (Amsterdam, Netherlands) · 2026
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Amanda J StockOklahoma Medical Research Foundation, Arthritis & Clinical Immunology, Oklahoma City, OK, United States.
Pierina Gonzalez ParedesOklahoma Medical Research Foundation, Arthritis & Clinical Immunology, Oklahoma City, OK, United States.
Luciana Previato de AlmeidaOklahoma Medical Research Foundation, Arthritis & Clinical Immunology, Oklahoma City, OK, United States.
Stanley D KosankeHeartland Veterinary Pathology Services, PLLC, Edmond, OK, United States.
Srinivaas ChetlurOklahoma Medical Research Foundation, Arthritis & Clinical Immunology, Oklahoma City, OK, United States.
Hannah BuddeOklahoma Medical Research Foundation, Arthritis & Clinical Immunology, Oklahoma City, OK, United States.
Paul WakenightSeattle Children's Research Institute, Center for Integrative Brain Research, Seattle, WA, United States.
Theresa A ZwingmanSeattle Children's Research Institute, Center for Integrative Brain Research, Seattle, WA, United States.
Aaron B I RosenSeattle Children's Research Institute, Center for Immunity and Immunotherapies, Seattle, WA, United States.
Eric J AllenspachSeattle Children's Research Institute, Center for Immunity and Immunotherapies, Seattle, WA, United States.
Kathleen J MillenSeattle Children's Research Institute, Center for Integrative Brain Research, Seattle, WA, United States.
Jane H BucknerBenaroya Research Institute at Virginia Mason, Center for Translational Immunology, Seattle, WA, United States.
David J RawlingsSeattle Children's Research Institute, Center for Immunity and Immunotherapies, Seattle, WA, United States.
Jacquelyn A GormanOklahoma Medical Research Foundation, Arthritis & Clinical Immunology, Oklahoma City, OK, United States.
Oklahoma Medical Research Foundation · USUniversity of Washington · USHeartland Research Associates · USVirginia Mason Medical Center · US

Funding

Viral sensor IFIH1 promotes SLE through an altered interferon programP20GM139763 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI Rajanarayanan S Srinivasan · 2021 to 2026
$20.3M
An integrated strategy to define the functional and synergistic impact of T1D causal variantsDP3DK111802 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI RAWLINGS, DAVID J · 2016 to 2016
$4.4M
Defining the functional impact of T1D genes in mouse and man: a unified strategyDP3DK097672 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI BUCKNER, JANE HOYT · 2012 to 2013
$4.4M
5-Laser Cytek Aurora Spectral Flow CytometerS10OD028479 · OD · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2020 to 2020
$317k
NIDDK NIH HHS DP3 DK097672NIDDK NIH HHS DP3 DK111802NIGMS NIH HHS P20 GM139763NIH HHS S10 OD028479
6 · The paper itself

Abstract

Type 1 diabetes (T1D) is an autoimmune disease in which pancreatic islet β-cells are attacked by the immune system, resulting in insulin deficiency and hyperglycemia. One of the top non-synonymous single-nucleotide polymorphisms (SNP) associated with T1D is in the interferon-induced helicase C domain-containing protein 1 (

Indexed as

Autoimmune DiseasesDiabetes Mellitus, Type 1AnimalsCD8-Positive T-LymphocytesDEAD-box RNA HelicasesFemaleGenetic Predisposition to DiseaseInterferon-Induced Helicase, IFIH1InterferonsMiceMice, Inbred NODDEAD-box RNA HelicasesInterferon-Induced Helicase, IFIH1InterferonsdiabetesIFIH1insulitisMDA5T cellstype I interferons

Identifiers

PMID38487540
PMCPMC10937421
OpenAlexW4392292613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.